A Phase 1/2 interventional study of Fludarabine, Busulfan, Thymoglobulin in Wiskott-Aldrich Syndrome, sponsored by The Korean Society of Pediatric Hematology Oncology. Completed at 1 site in South Korea. Open to participants aged 1 Year to 25 Years. Per ClinicalTrials.gov, last updated 2014-07-14.
Sponsored by The Korean Society of Pediatric Hematology Oncology · Phase 1/2, Interventional, and Treatment
Wiskott-Aldrich syndrome (WAS) is a rare X-linked congenital immune-deficiency syndrome and hematopoietic stem cell transplantation (HSCT) has become a curative modality. But the transplant with the conventional conditioning resulted in high incidence of treatment related toxicities and non-myeloablative conditioning resulted in high incidence of engraftment failure. Recently, fludarabine based reduced toxicity myeloablative conditioning regimen was developed for adult myeloid malignancies with promising result of good engraftment and low treatment related toxicities. To increase the engraftment potential without serious complication, reduced toxicity myeloablative conditioning regimen composed of fludarabine, busulfan, and thymoglobulin is designed for Wiskott-Aldrich syndrome.
Wiskott-Aldrich syndrome (WAS) is an rare X-linked congenital immune-deficiency syndrome characterized by the triad of recurrent infection, eczema and thrombocytopenia with small size of platelet (Puck JM, 2006). Clinical studies revealed high rate of autoimmune disorder and malignancy in WAS (Ochs HD, 2006). The identification of the molecular defect in 1994 (Derry JM, 1994) has broadened the clinical spectrum of the syndrome to include chronic or intermittent X-linked thrombocytopenia (XLT), a relatively mild form of WAS and X-lined neutropenia caused by an arrest of myelopoiesis (Ochs HD, 2006).
The incidence of WAS in Korea was very low and only 6 patients diagnosed between 2001 and 2005 (Kim JG, 2006).
Conventional treatments for WAS such as prophylactic antibiotics and immune globin for infection and platelet transfusion for bleeding were not so successful (Thrasher AJ, 2000). Bone marrow transplantation (BMT) from an HLA-matched related donor is an effective treatment (Filipovich AH, 2001) and patients without appropriate related donor could receive alternative stem cell source such as matched unrelated donor or cord blood. But the transplant with the alternative donor needed more intensive conditioning to overcome the hematologic and immunologic barrier with increased treatment related toxicity. Further progress depends in particular on the development of alternative preparative conditioning regimens which allow stable engraftment of donor precursor cells with minimal systemic toxic side effects (Friedrich W, 2004).
Recently, we reported successful unrelated bone marrow transplantation in a boy with WAS with reduced toxicity myeloablative conditioning regimen to increase the engraftment potential without serious complication (Kang, 2008), and extended to multicenter phase I/II pilot study with this reduced toxicity myeloablative conditioning regimen in the HSCT for WAS.
37 studies on the registry are indexed under Wiskott-Aldrich Syndrome; 4 are open to participants now.
This study's planned enrollment of 5 is below the median of 18 across 26 interventional studies indexed under Wiskott-Aldrich Syndrome.
Browse Wiskott-Aldrich Syndrome studies →The Korean Society of Pediatric Hematology Oncology is the lead sponsor of 7 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must be free of significant functional deficits in major organs, but the following eligibility criteria may be modified in individual cases:
Exclusion Criteria:
Drug: Fludarabine, Busulfan, Thymoglobulin
Drug pages: Fludarabine · Busulfan · Thymoglobulin
fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 \& -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, \& -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, -6 for cord blood and on days -4, -3, -2 for bone marrow or mobilized peripheral blood)
To evaluate the engraftment potential of fludarabine, busulfan plus thymoglobulin conditioning regimen for HSCT in WAS.
Time frame: Feb. 2007 to Jan. 2012
To evaluate the incidence and severity of toxicity and treatment related mortality.
Time frame: Feb. 2007 to Jan. 2012
To evaluate overall and event free survival rate.
Time frame: Feb. 2007 to Jan. 2012
To evaluate acute and chronic graft versus host disease (GVHD).
Time frame: Feb. 2007 to Jan. 2012
To evaluate immunologic recovery after HSCT.
Time frame: Feb. 2007 to Jan. 2012
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fludarabine · Busulfan · Thymoglobulin
The Korean Society of Pediatric Hematology Oncology